The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans.
本发明涉及2-((1R,4R)-4-(4-(5-(苯并[d]
噁唑-2-基
氨基)
吡啶-2-基)苯基)环己基)
乙酸盐的新晶型及其在治疗或预防与动物(尤其是人类)DGAT1活性相关的疾病或疾病中的应用。